IRIS
AVOLIO, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.167
NA - Nord America 3.153
AS - Asia 2.354
SA - Sud America 475
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 9
Totale 9.218
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.098
SG - Singapore 921
IE - Irlanda 887
CN - Cina 744
UA - Ucraina 485
BR - Brasile 394
SE - Svezia 389
IT - Italia 348
RU - Federazione Russa 295
HK - Hong Kong 281
DE - Germania 251
FI - Finlandia 152
VN - Vietnam 145
FR - Francia 134
IN - India 88
GB - Regno Unito 82
TR - Turchia 66
BE - Belgio 39
AR - Argentina 34
AT - Austria 25
CA - Canada 25
NL - Olanda 19
BD - Bangladesh 17
ID - Indonesia 16
MX - Messico 16
EU - Europa 15
IR - Iran 12
PL - Polonia 12
EC - Ecuador 11
VE - Venezuela 11
CZ - Repubblica Ceca 10
ES - Italia 10
IQ - Iraq 9
JP - Giappone 9
ZA - Sudafrica 9
CL - Cile 8
PK - Pakistan 8
AU - Australia 7
CO - Colombia 6
SC - Seychelles 6
LT - Lituania 5
MA - Marocco 5
PT - Portogallo 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
CR - Costa Rica 4
DZ - Algeria 4
PY - Paraguay 4
UZ - Uzbekistan 4
XK - ???statistics.table.value.countryCode.XK??? 4
HN - Honduras 3
PE - Perù 3
PH - Filippine 3
SN - Senegal 3
TN - Tunisia 3
AL - Albania 2
BH - Bahrain 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
EE - Estonia 2
EG - Egitto 2
HR - Croazia 2
JO - Giordania 2
KE - Kenya 2
KR - Corea 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MN - Mongolia 2
MU - Mauritius 2
MY - Malesia 2
NP - Nepal 2
RO - Romania 2
AD - Andorra 1
AM - Armenia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
BZ - Belize 1
CI - Costa d'Avorio 1
CM - Camerun 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
JM - Giamaica 1
MD - Moldavia 1
MM - Myanmar 1
NE - Niger 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TO - Tonga 1
Totale 9.216
Salva come PNG Salva come JPEG
Città #
Dublin 886
Chandler 403
Singapore 350
Jacksonville 326
Nyköping 286
Hong Kong 276
Dearborn 269
Ashburn 216
Beijing 210
Dallas 162
Nanjing 145
Santa Clara 130
Princeton 90
Wilmington 89
Munich 76
Helsinki 70
Moscow 66
Nanchang 65
Woodbridge 60
Ann Arbor 58
New York 53
The Dalles 53
San Mateo 51
Ho Chi Minh City 46
Brussels 39
Boardman 37
Los Angeles 37
Hanoi 34
Des Moines 33
Jiaxing 33
Turku 33
São Paulo 31
Shenyang 30
Foggia 29
Tianjin 25
Nuremberg 24
Cedar Knolls 21
Changsha 21
Hebei 21
Kunming 19
Rome 18
Milan 16
Naples 16
Guangzhou 15
Zhengzhou 15
Bari 14
Hangzhou 14
Rio de Janeiro 14
Chicago 13
Seattle 13
Council Bluffs 12
San Severo 12
Falkenstein 11
Hilden 11
Ningbo 11
Norwalk 11
Redwood City 11
Taizhou 11
Curitiba 10
Frankfurt am Main 10
Jinan 10
Belo Horizonte 9
Brasília 9
Kocaeli 9
Pimonte 9
San Francisco 9
Warsaw 9
Assago 8
Auburn Hills 8
Buffalo 8
Fortaleza 8
Lanzhou 8
Tokyo 8
Boston 7
Brooklyn 7
Falls Church 7
London 7
Montreal 7
Vienna 7
Atlanta 6
Biên Hòa 6
Bắc Ninh 6
Hanover 6
Jakarta 6
Johannesburg 6
Ottawa 6
Porto Alegre 6
Pune 6
Ribeirão Preto 6
Toronto 6
Wuhan 6
Bologna 5
Düsseldorf 5
Haiphong 5
Manaus 5
Mexico City 5
Ninh Bình 5
Quito 5
Santeramo In Colle 5
Stockholm 5
Totale 5.432
Salva come PNG Salva come JPEG
Nome #
Do patients and referral centers characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register 181
Serum Soluble Intercellular Adhesion Molecule-1 in MS: relation to clinical and Gd-MRI activity, and to rIFNβ-1b treatment. 133
Serial immunoprecipitation assays for interferon-(IFN)-beta antibodies in multiple sclerosis patients. 130
Defining the electroclinical phenotype and outcome of PCDH19‐related epilepsy: A multicenter study 129
Changes of serum ICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. 125
The epilepsy phenotype in adult patients with intellectual disability and pathogenic copy number variants 125
Comparison of Clinical and demographic features between affected pairs of Italian Multiple Sclerosis Multiplex families; relation to Tumor Necrosis Factor genomic polymorphisms. 124
Intravenous lacosamide in seizure emergencies: Observations from a hospitalized in-patient adult population. 124
Analisi fenotipica di linfociti T di pazienti con Sclerosi multipla (SM) nel sangue periferico ed in coltura con e senza aggiunta di mitogeni 123
Adhesion molecules and matrix metalloproteinases in MS: effects induced by Interferon beta. 121
Espressione di LFA-1 su linfociti memoria CD4+CD45RO+ si sangue periferico nella Sclerosi Multipla remittente: effetti indotti dall’ IFN b-1a. 120
CSF and serum soluble adhesion molecules in Multiple Sclerosis 119
Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate in Cystic Fibrosis Bronchial Epithelial Cells 119
Disease duration, relapse rate and clinical course in Multiple Sclerosis. Relation to IgG production within the blood-brain barrier. 116
Design of a European multicenter study dedicated to the evaluation of the EDMUS system: EVALUED. 116
Usefulness of a standardized method for collecting anamnestic data in multiple sclerosis (MS). 114
Analisi liquorale per la diagnosi ed il follow-up di malattie infiammatorie del SNC. 113
Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. 112
Counting of peripheral extracellular vesicles in Multiple Sclerosis patients by an improved nanoplasmonic assay and dynamic light scattering 111
Italian cohort of Lafora disease: Clinical features, disease evolution, and genotype-phenotype correlations 111
Between-laboratory variability in oligoclonal IgG band numbering. 110
Intrathecal IgG synthesis and clinical course in Multiple Sclerosis 110
European Validation of a Standardized Clinical Description of Multiple Sclerosis. 108
Age-Related Disability in Multiple Sclerosis. 108
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. 108
L’ esame del liquor (CSF) nella diagnosi di Sclerosi Multipla (SM) 107
T regulatory cells are markers of disease activity in multiple sclerosis patients. 107
Wernicke's encephalopathy following reduced food intake due to depressive disorders. 106
Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-1a. 105
New Insights Into Immune Cell-Derived Extracellular Vesicles in Multiple Sclerosis. 105
Tremor, sensory-motor polyneuropathy and cerebral gliosis in klinefelter's syndrome 104
Epstein–Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role? 103
Soluble Intercellular Adhesion Molecule-1 in serum and cerebrospinal fluid (CSF) of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA Magnetic Resonance Imaging enhancement and CSF findings. 102
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in Multiple Sclerosis: relationships with different MRI measures of disease activity during IFN-beta-1a treatment. 101
Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. 101
Soluble Intercellular adhesion molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and the peripheral nervous system. 99
Late-onset Leber hereditary optic neuropathy mimiking Susac’s syndrome 99
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 99
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis 98
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. 98
Il ruolo dell’ esame del liquor 98
Soluble Intercellular Adhesion Molecule-1 (sICAM-1) nel siero e liquor di pazienti con sclerosi multipla remittente clinicamente attiva: correlazioni con lesioni RMI che assumono gadolinio e con parametri liquorali 98
Effects of rIFNbeta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells. 97
Serum MMP-2 and MMP-9 are elevated in different Multiple Sclerosis subtypes. 95
LFA-1 expressing CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNbeta-1a. 94
Perceptive and Subjective Evaluation of Speech Disorders in Parkinson's Disease 94
First-aid management of tonic-clonic seizures among healthcare personnel: A survey by the Apulian section of the Italian League Against Epilepsy 94
Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. 93
Quantitation of intrathecal measles virus IgG antibody synthesis rate: Subacute sclerosing panencephalitis and multiple sclerosis. 93
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 92
Interferon beta in relapsing / remitting multiple sclerosis: an independent postmarketing study in southern Italy. 92
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients. 91
P2X7 purinergic receptor on monocytes of patients with Multiple Sclerosis: effects of Glatiramer Acetate immune modulation 91
Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients. 91
An Italian multicentre study of perampanel in progressive myoclonus epilepsies 90
Brivaracetam in Absence Status Epilepticus 89
Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register 89
How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study. 88
Prognostic indicators in pediatric clinically isolated syndrome. 88
Immune and central nervous system-related miRNAs expression profiling in monocytes of multiple sclerosis patients. 88
Glatiramer Acetate in Multiple Sclerosis: a review 87
Usefulness of a standardised collection of disease events for clinical studies in Multiple Sclerosis. 87
Faciobrachial dystonic seizures expressed as epileptic spasms, followed by focal seizures in anti-LGI1 encephalitis: a video-polygraphic study. 87
Pharmacological treatment of depression in Alzheimer's disease: A challenging task 87
Krebs cycle derivatives, dimethyl fumarate and itaconate, control metabolic reprogramming in inflammatory human microglia cell line 86
Effetti antinfiammatori dell’ Interferone beta-1b ricombinante nella Sclerosi Multipla: studio longitudinale dei livelli sierici della forma solubile di Intercellular Adhesion Molecule-1 (sICAM-1) e dei subsets linfocitari 86
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. 86
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 86
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 86
From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases 82
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 81
Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease 81
Fisiopatologia della risposta immunitaria nel compartimento liquorale. XXXVII Congress of the Italian Neurological Society, Bari 14-18 October 2006. 80
The effect of quarantine due to Covid-19 pandemic on seizure frequency in 102 adult people with epilepsy from Apulia and Basilicata regions, Southern Italy 79
Fluctuations of MS births and UV-light exposure. 79
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion. 78
Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production. 76
The Italian multiple sclerosis register 75
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders 74
IgG and IgM antibodies to the refolded MOG(1-125) extracellular domain in humans. 73
Molecular Characterization of Peripheral Extracellular Vesicles in Clinically Isolated Syndrome: Preliminary Suggestions from a Pilot Study 73
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 72
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives 72
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. 70
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 69
Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders 67
Treatment with metformin in twelve patients with Lafora disease 67
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 67
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 63
Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer's disease 61
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 59
Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression (Q1 WoS) 58
Guillain-Barré syndrome as only manifestation of COVID-19 infection 56
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 53
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries 52
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 51
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 51
THE PRESENTING SYMPTOMS OF LAFORA DISEASE: AN ELECTROCLINICAL AND GENETIC STUDY IN FIVE APULIAN (SOUTHERN ITALY) FAMILIES 49
Myeloid-derived Suppressor Cells and Multiple Sclerosis 48
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 48
Totale 9.231
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.940
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.940
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021376 0 0 0 0 0 28 93 46 92 110 3 4
2021/2022540 70 12 16 15 41 10 19 30 66 56 40 165
2022/20232.491 198 129 105 157 119 191 18 144 1.049 117 186 78
2023/2024389 65 55 23 24 43 69 32 17 4 8 18 31
2024/20252.252 64 37 55 54 57 247 194 174 483 156 247 484
2025/20261.909 222 446 395 524 223 99 0 0 0 0 0 0
Totale 10.251